Valuation: Tonix Pharmaceuticals

Market Cap 22Cr 19Cr 18Cr 16Cr 30Cr 2.08TCr 31Cr 207.3Cr 81Cr 1.04TCr 82Cr 80Cr 3.47TCr P/E 2026 *
-1.31x
P/E 2027 * -2.06x
Enterprise Value 22Cr 19Cr 18Cr 16Cr 30Cr 2.08TCr 31Cr 207.3Cr 81Cr 1.04TCr 82Cr 80Cr 3.47TCr EV / Sales 2026 *
3.89x
EV / Sales 2027 * 1.88x
Free-Float
99.87%
Yield 2026 *
-
Yield 2027 * -
10/08 Tonix Pharmaceuticals Holding Corp., Q2 2026 Earnings Call, Aug 10, 2026
10/08 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
03/08 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
22/07 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
15/07 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
13/07 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
13/07 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
29/06 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
29/06 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
25/06 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
08/06 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
08/06 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
29/05 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%+2.32% - - 22Cr
-2.25%-0.47%+68.30%+116.05% 1,05200Cr
-0.66%+0.43%+47.39%+51.02% 63TCr
-0.54%+1.39%+20.69%+64.61% 44TCr
-1.99%-3.32%+38.71%+36.26% 35TCr
-1.05%-2.81%+23.07%+35.91% 29TCr
-2.12%-3.67%-1.14%+5.35% 24TCr
-0.63%+1.04%+40.05%+56.67% 22TCr
-1.19%-3.41%-9.57%-53.50% 20TCr
+0.16%+3.87%+16.89%+77.38% 17TCr
Average -1.26%-0.77%+27.15%+43.31% 39.95TCr
Weighted average by Cap. -1.36%-0.63%+39.09%+61.76%

Financials

2026 *2027 *
Net sales 5.6Cr 4.84Cr 4.55Cr 4.14Cr 7.78Cr 535.85Cr 7.9Cr 53Cr 21Cr 268.33Cr 21Cr 21Cr 891.71Cr 12Cr 10Cr 9.43Cr 8.57Cr 16Cr 1.11TCr 16Cr 110.44Cr 43Cr 556.13Cr 44Cr 43Cr 1.85TCr
Net income -17Cr -14Cr -14Cr -12Cr -23Cr -1.61TCr -24Cr -159.65Cr -62Cr -803.87Cr -63Cr -62Cr -2.67TCr -15Cr -13Cr -12Cr -11Cr -21Cr -1.46TCr -22Cr -145.34Cr -57Cr -731.84Cr -57Cr -56Cr -2.43TCr
Net Debt - -
Logo Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.71USD
Average target price
42.40USD
Spread / Average Target
+233.60%

Quarterly revenue - Rate of surprise